323 related articles for article (PubMed ID: 32661823)
1. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Smith PL; Yogaratnam Y; Samad M; Kasow S; Dalgleish AG
Clin Transl Oncol; 2021 Jan; 23(1):110-121. PubMed ID: 32661823
[TBL] [Abstract][Full Text] [Related]
2. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
[TBL] [Abstract][Full Text] [Related]
4. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
5. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.
Soeda A; Morita-Hoshi Y; Makiyama H; Morizane C; Ueno H; Ikeda M; Okusaka T; Yamagata S; Takahashi N; Hyodo I; Takaue Y; Heike Y
Jpn J Clin Oncol; 2009 Dec; 39(12):797-806. PubMed ID: 19797418
[TBL] [Abstract][Full Text] [Related]
6. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway.
Pei Q; Pan J; Ding X; Wang J; Zou X; Lv Y
Pancreatology; 2015; 15(3):233-9. PubMed ID: 25937078
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
[TBL] [Abstract][Full Text] [Related]
9. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
Plate JM; Plate AE; Shott S; Bograd S; Harris JE
Cancer Immunol Immunother; 2005 Sep; 54(9):915-25. PubMed ID: 15782312
[TBL] [Abstract][Full Text] [Related]
10. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
[TBL] [Abstract][Full Text] [Related]
11. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Miyashita T; Miki K; Kamigaki T; Makino I; Nakagawara H; Tajima H; Takamura H; Kitagawa H; Fushida S; Ahmed AK; Duncan MD; Harmon JW; Ohta T
Clin Exp Med; 2017 Feb; 17(1):19-31. PubMed ID: 26449615
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.
Liu WM; Fowler DW; Smith P; Dalgleish AG
Br J Cancer; 2010 Jan; 102(1):115-23. PubMed ID: 19997099
[TBL] [Abstract][Full Text] [Related]
13. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
14. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Xu X; Rao GS; Groh V; Spies T; Gattuso P; Kaufman HL; Plate J; Prinz RA
BMC Cancer; 2011 May; 11():194. PubMed ID: 21605422
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
Selvanesan BC; Meena K; Beck A; Meheus L; Lara O; Rooman I; Gravekamp C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33154149
[TBL] [Abstract][Full Text] [Related]
17. In vitro immunomodulatory properties of gemcitabine alone and in combination with interferon-alpha.
Fritz J; Karakhanova S; Brecht R; Nachtigall I; Werner J; Bazhin AV
Immunol Lett; 2015 Nov; 168(1):111-9. PubMed ID: 26450014
[TBL] [Abstract][Full Text] [Related]
18. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
19. Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F; De Gooijer CJ; van Gulijk M; Lukkes M; Klaase L; Lievense LA; Waasdorp C; Jebbink M; Bootsma GP; Stigt JA; Biesma B; Kaijen-Lambers MEH; Mankor J; Vroman H; Cornelissen R; Baas P; Van der Noort V; Burgers JA; Aerts JG
EBioMedicine; 2021 Feb; 64():103160. PubMed ID: 33516644
[TBL] [Abstract][Full Text] [Related]
20. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
